Cue Biopharma
92 hedge funds and large institutions have $291M invested in Cue Biopharma in 2020 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 40 increasing their positions, 23 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
26% less capital invested
Capital invested by funds: $393M → $291M (-$102M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
39% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 18
Holders
92
Holding in Top 10
2
Calls
$636K
Puts
$453K
Top Buyers
| 1 | +$11.7M | |
| 2 | +$9.22M | |
| 3 | +$7.28M | |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$6.01M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.91M |
Top Sellers
| 1 | -$3.57M | |
| 2 | -$1.46M | |
| 3 | -$1.14M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$834K |
| 5 |
Citigroup
New York
|
-$648K |